SEC Form 4 · accession 0001209191-17-043695
Juno Therapeutics, Inc. · JUNO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Harr
Officer — CFO & Head, Corp. Development
Period of report
Jul 3, 2017
Accepted (ET)
Jul 5, 2017 · 6:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001594864
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 3, 2017 | M | 8,750 | $8.72 | A | 736,189 | D | |
| Common StockF1 | Jul 3, 2017 | S | 8,750 | $30.00 | D | 727,439 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $8.72 | Jul 3, 2017 | M | 8,750 | D | — | Nov 13, 2024 | Common Stock | 8,750 | 107,500 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2014, as amended March 24, 2015.
- F21/48th of the shares subject to the option vested and became exercisable on December 14, 2014 and 1/48th of the shares subject to the option shall vest monthly thereafter.